Adult Vaccines Market Size, Growth, Share and Forecast 2032

Market Overview:

The Adult Vaccines Market is projected to grow from USD 27655 million in 2024 to an estimated USD 43122.33 million by 2032, with a compound annual growth rate (CAGR) of 5.71% from 2024 to 2032.

The Adult Vaccines Market key market drivers include the growing prevalence of infectious diseases and the aging population, which has heightened the need for adult immunization programs. Governments and healthcare organizations are promoting vaccine uptake through public awareness campaigns and increasing funding for vaccination initiatives, particularly targeting chronic diseases and conditions affecting older adults. Additionally, advancements in biotechnology have led to the development of more effective and safer vaccines. The COVID-19 pandemic has further underscored the importance of vaccination, catalyzing innovation and infrastructure development within the sector. As chronic diseases such as diabetes and cardiovascular diseases become more widespread, demand for vaccines to prevent related infections is expected to rise, boosting market growth.

From a regional perspective, North America dominates the adult vaccines market, driven by high healthcare expenditure, well-established healthcare infrastructure, and significant government support for vaccination programs. The region also benefits from strong awareness and acceptance of vaccines among the adult population. Europe follows closely, supported by robust healthcare policies and initiatives by the European Union to enhance vaccine coverage. In the Asia-Pacific region, rapid urbanization, rising healthcare investments, and growing public awareness about the importance of adult immunization are driving market growth. Countries like China and India are emerging as significant markets due to their large populations and increasing healthcare access, while Latin America and the Middle East & Africa are also witnessing gradual market expansion due to improving healthcare infrastructure.

Market Drivers:

Growing Prevalence of Infectious Diseases:

One of the primary drivers of the adult vaccines market is the increasing prevalence of infectious diseases worldwide. As people age, their immune systems weaken, making them more vulnerable to infections. Diseases like influenza, pneumococcal infections, and hepatitis pose significant health risks to adults, particularly those over 60. The rising incidence of chronic diseases, such as diabetes, cancer, and cardiovascular disorders, further exacerbates the need for adult vaccines, as these conditions often impair the immune system. This growing disease burden has prompted healthcare providers and governments to intensify efforts toward immunization programs targeting adults to reduce infection-related morbidity and mortality rates.

Aging Population and Increasing Healthcare Expenditure:

The world's population is aging, with the number of people aged 60 and above increasing rapidly. In England, the number of people aged 50 and over has increased by over 6.8 million (a 47% increase) in the last 40 years4. As people age, they become more susceptible to vaccine-preventable diseases, and immunization becomes a critical component of preventive healthcare. The rise in healthcare expenditure, especially in developed economies, has enabled governments and healthcare organizations to allocate more resources toward the development and distribution of adult vaccines. For example, The US spends about $26.5 billion annually treating four major vaccine-preventable diseases (influenza, pneumococcal disease, shingles and pertussis) among US adults ages 50 years and older. Additionally, the increased focus on preventive care and cost-effective healthcare solutions has encouraged both public and private sectors to invest in vaccination programs that target the aging population, thereby boosting the market.

Technological Advancements in Vaccine Development:

Technological advancements in biotechnology and immunology are playing a pivotal role in the expansion of the adult vaccines market. Innovations such as recombinant vaccines, adjuvants, and mRNA-based vaccines have led to the development of safer, more effective, and longer-lasting vaccines. The rapid development of COVID-19 vaccines has accelerated progress in the overall vaccine industry, with novel platforms now being applied to other infectious diseases. These technological breakthroughs have not only improved vaccine efficacy but also shortened the time required for vaccine development and approval. This has significantly boosted the availability of new vaccines and encouraged higher adoption rates among the adult population, further propelling market growth.

Government Initiatives and Public Awareness Campaigns:

Government initiatives and public health campaigns have been instrumental in driving the demand for adult vaccines. Many governments, particularly in developed countries, have implemented policies that promote adult vaccination as part of routine healthcare. Public awareness campaigns have also played a significant role in educating adults about the benefits of vaccines, leading to higher immunization rates. The COVID-19 pandemic has amplified the importance of vaccination, with many countries adopting more aggressive vaccination strategies that include adults. For instance, the CDC recommends that persons ≥65 years of age should receive an additional dose of 2023–2024 Formula COVID-19 vaccine. Increased public funding, subsidies for vaccine purchases, and global initiatives from organizations like the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) are further encouraging widespread immunization efforts, thus driving the growth of the adult vaccines market.

Market Trends:

Increasing Focus on Adult Immunization Programs:

A significant trend in the adult vaccines market is the growing emphasis on adult immunization programs by both governments and healthcare organizations. Traditionally, vaccination efforts have been primarily focused on children, but there is now a shift toward addressing the vaccination needs of adults, particularly those in high-risk groups such as the elderly and individuals with chronic illnesses. This shift is driven by the recognition that vaccine-preventable diseases in adults pose serious public health risks and contribute to significant healthcare costs. As a result, several countries have launched national immunization plans aimed specifically at increasing vaccine coverage among adults, thereby enhancing the market’s growth potential.

Technological Innovations in Vaccine Platforms:

Advancements in vaccine technologies are another critical trend shaping the adult vaccines market. The development of new vaccine platforms, such as mRNA technology, viral vector vaccines, and recombinant protein vaccines, has revolutionized the vaccine industry. For example, the success of mRNA COVID-19 vaccines has demonstrated the potential of new platforms. Studies have shown that mRNA COVID-19 vaccines are highly effective, with 2-3 doses providing 90% protection against invasive mechanical ventilation or death, even during the Omicron period. These innovations have enabled faster development times, enhanced immune responses, and improved safety profiles for adult vaccines. The success of COVID-19 vaccines, particularly those using mRNA technology, has paved the way for broader applications of these platforms to other infectious diseases affecting adults. This trend is expected to accelerate the introduction of new vaccines and provide opportunities for addressing diseases that have traditionally been challenging to target with conventional vaccine technologies.

Rising Demand for Combination Vaccines:

The demand for combination vaccines is gaining momentum in the adult vaccines market as healthcare providers and patients seek convenient and efficient immunization solutions. Combination vaccines, which protect against multiple diseases in a single shot, are becoming increasingly popular among adults, particularly those with busy lifestyles or limited access to healthcare services. These vaccines reduce the number of injections required, improve compliance with vaccination schedules, and enhance the overall vaccination experience. Pharmaceutical companies are actively developing combination vaccines for adults, addressing multiple infectious diseases such as influenza, tetanus, diphtheria, and pertussis, which is expected to drive market expansion in the coming years.

Growing Awareness of the Importance of Preventive Healthcare:

The growing awareness of the importance of preventive healthcare is driving a shift in public attitudes toward vaccines, particularly among adults. With rising healthcare costs and an aging population, there is an increasing focus on preventive measures that can reduce the burden of disease and lower long-term healthcare expenses. Vaccines have emerged as a critical tool in this preventive strategy, leading to heightened awareness about the benefits of adult vaccination. For example, in 2018, hepatitis B vaccination coverage among adults aged ≥19 years was 30.0%, Tdap coverage among adults aged 19-64 years was 31.2%, and herpes zoster coverage among adults aged ≥60 years was 34.9%. While these rates have increased over time, they remain well below target levels, indicating room for continued growth as awareness improves. Public health campaigns, educational initiatives, and media coverage have all contributed to greater vaccine acceptance among adults, resulting in higher immunization rates. This trend is expected to continue as more individuals recognize the value of vaccines in protecting against serious health risks.

Market Restraints and Challenges:

High Development Costs and Lengthy Regulatory Processes:

One of the major restraints in the adult vaccines market is the high cost of vaccine development and the lengthy regulatory approval process. Vaccine development requires substantial investment in research and clinical trials, often taking years before a product can be brought to market. The costs involved in developing vaccines, including testing for safety and efficacy, are significantly higher compared to other pharmaceutical products. Moreover, the regulatory framework governing vaccines is stringent, and gaining approval from health authorities such as the FDA, EMA, or WHO can be time-consuming. These factors limit the number of new vaccines entering the market, slowing down innovation and market expansion.

Vaccine Hesitancy and Lack of Awareness:

Vaccine hesitancy remains a persistent challenge in the adult vaccines market. Despite the proven efficacy of vaccines in preventing infectious diseases, there is a segment of the adult population that is reluctant to receive vaccines due to misinformation, fear of side effects, or distrust in the healthcare system. This hesitancy is particularly prevalent in certain regions and among specific demographic groups, which can lead to lower vaccination rates and reduce overall market potential. In addition to vaccine hesitancy, a lack of awareness about the availability and importance of adult vaccines further hampers market growth, particularly in low- and middle-income countries.

Inadequate Access to Vaccination Services:

Limited access to vaccination services, especially in remote or underserved areas, poses another significant challenge to the growth of the adult vaccines market. While developed regions have established healthcare infrastructures that support widespread vaccine distribution, many developing regions face challenges in ensuring the availability and accessibility of vaccines for adults. Inadequate healthcare facilities, insufficient funding, and logistical barriers in distributing vaccines to rural or marginalized populations create disparities in immunization coverage, which limits market expansion in these areas.

Market Segmentation Analysis:

By technology, the market includes live attenuated, inactivated, subunit, toxoid, conjugate, and other vaccines. Live attenuated vaccines, which contain weakened forms of the virus, are commonly used for diseases like measles and rubella, offering long-lasting immunity. Inactivated vaccines, which use killed pathogens, are frequently employed for influenza. Subunit and conjugate vaccines, targeting specific parts of the pathogen, are growing in demand due to their improved safety profiles. The toxoid segment, used for diseases like tetanus, also holds a steady share of the market.

By vaccine type, the market is divided into monovalent and multivalent vaccines. Monovalent vaccines target a single strain or pathogen, while multivalent vaccines cover multiple strains or diseases in one dose, making them more convenient for healthcare providers and patients alike. Multivalent vaccines are increasingly preferred, especially for adults seeking comprehensive protection with fewer injections.

By end use, the market is segmented into private healthcare firms and government hospitals. Private healthcare firms dominate in regions with high healthcare expenditure, where consumers seek convenience and personalized care. Government hospitals play a crucial role in public vaccination programs, particularly in emerging markets where government-led initiatives drive widespread immunization coverage. Both segments are essential in ensuring broad access to adult vaccines, each catering to different patient demographics and healthcare infrastructures.

Segmentation:

By Technology

• Live Attenuated
• Inactivated
• Subunit
• Toxoid
• Conjugate
• Others

By Vaccine Type 

• Monovalent
• Multivalent

By End Use 

• Private Healthcare Firms
• Government Hospitals

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Argentina
  • Chile
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Nigeria

Regional Analysis:

North America

North America holds the largest market share, accounting for approximately 40% of the global adult vaccines market. The region's dominance is driven by a well-established healthcare system, high healthcare spending, and robust vaccination programs. The United States, in particular, has a high rate of vaccine adoption due to government support, advanced biotechnology, and public awareness campaigns. Seasonal flu vaccination and vaccines targeting chronic conditions are prevalent in the region, while COVID-19 vaccine efforts have further bolstered market growth. Canada also plays a significant role, with strong government initiatives supporting adult immunization.

Europe

Europe follows closely, contributing around 30% to the global market share. The region benefits from comprehensive public health policies and strong government involvement in vaccine procurement and distribution. European countries, such as Germany, the UK, and France, have well-established adult vaccination programs that cover a broad spectrum of diseases, including pneumococcal infections, hepatitis, and influenza. The European Union’s focus on preventive healthcare and coordinated vaccination strategies across member states has fostered high vaccine coverage among adults, enhancing market growth in the region.

Asia-Pacific

The Asia-Pacific region is the fastest-growing market, holding approximately 20% of the global market share and showing substantial potential for future expansion. The growth in this region is driven by rising healthcare investments, an increasing aging population, and growing awareness of adult vaccination. Countries such as China, Japan, and India are key contributors, with large populations and expanding healthcare infrastructure. Governments in these countries are increasingly prioritizing vaccination programs to address infectious diseases among adults. In addition, the region's growing urbanization and improvements in healthcare access are accelerating market growth.

Latin America

Latin America holds a smaller share of the adult vaccines market, approximately 5%, but is witnessing steady growth. Countries like Brazil and Mexico are leading the region’s market, driven by increasing government focus on immunization and improving healthcare systems. Public health campaigns to address diseases such as hepatitis and influenza are becoming more common, contributing to the gradual expansion of the adult vaccines market in this region.

Middle East & Africa

The Middle East & Africa region captures around 5% of the global market share, with growth primarily centered in countries with stronger healthcare systems, such as the UAE and South Africa. However, overall market development is hindered by limited healthcare access and lower public awareness about adult vaccination in many parts of the region. Ongoing efforts by international organizations to promote immunization and improve healthcare infrastructure are expected to drive gradual growth in the market over the coming years.

Key Player Analysis:

• Astrazeneca
• Glaxosmithkline
• Johnson & Johnson
• Merck & Co
• Novartis
• Sanofi
• Serum Institute India

Competitive Analysis:

The adult vaccines market is highly competitive, with several global pharmaceutical companies dominating the landscape. Key players such as Pfizer, GlaxoSmithKline (GSK), Merck & Co., and Sanofi lead the market due to their extensive product portfolios, strong R&D capabilities, and global distribution networks. These companies invest heavily in developing new vaccines and improving existing ones to maintain their market position, particularly focusing on innovative technologies like mRNA and recombinant vaccines. Emerging biotech firms are also entering the market, contributing to increasing competition, especially in niche vaccine segments. Strategic partnerships, mergers, and acquisitions are common as companies seek to expand their market share and improve their product offerings. Additionally, government contracts and collaborations with public health organizations play a crucial role in securing a competitive edge, as large-scale vaccination programs are key revenue drivers in the adult vaccines market.

Recent Developments:

• In April 2024, Merck presented the results of its Phase 3 trial STRIDE-10 at the 34th ESCMID Global conference in Barcelona, Spain. The trial evaluated Merck’s 21-valent pneumococcal conjugate vaccine, V116, specifically developed for adults. It compared the safety, immunogenicity, and tolerability of V116 against PPSV23, a 23-valent pneumococcal polysaccharide vaccine, in adults aged 50 and older who had not previously received pneumococcal vaccination.
• In August 2022, the WHO Strategic Advisory Group of Experts on Immunization (SAGE) released interim recommendations for the use of the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine. According to SAGE, the Pfizer-BioNTech mRNA vaccine is safe and effective. These recommendations were part of a broader guidance document, providing key insights into the vaccine's use during the ongoing pandemic.

Market Concentration & Characteristics:

The adult vaccines market is moderately concentrated, with a few dominant players such as Pfizer, GlaxoSmithKline (GSK), Merck & Co., and Sanofi controlling a significant portion of the market. These companies have established strong global distribution networks, extensive R&D capabilities, and broad product portfolios, allowing them to maintain a competitive advantage. Their leadership is bolstered by large-scale manufacturing capacity and strategic collaborations with governments and health organizations for vaccine distribution. The market is characterized by high barriers to entry due to the substantial investment required for vaccine development, rigorous regulatory approvals, and the complexity of clinical trials. Despite this, the market is dynamic, with emerging biotechnology firms increasingly entering niche areas. Ongoing innovation in vaccine technologies, such as mRNA and conjugate vaccines, is shaping the future landscape of adult immunization, further intensifying competition among established players.

Report Coverage:

The research report offers an in-depth analysis based on By Technology, By Vaccine Type  and By End Use. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

1. Increasing global awareness of vaccine-preventable diseases will drive higher adult vaccination rates.
2. Ongoing technological advancements, such as mRNA and recombinant vaccines, will enhance vaccine efficacy and safety.
3. Government initiatives and funding for adult immunization programs will support widespread vaccine access.
4. The aging population will create a growing demand for vaccines targeting chronic diseases.
5. Combination vaccines will become more popular, offering protection against multiple diseases in a single dose.
6. Emerging markets in Asia-Pacific and Latin America will present significant growth opportunities due to improving healthcare infrastructures.
7. Rising healthcare costs will push consumers toward preventive measures, increasing vaccine uptake.
8. Strategic partnerships and collaborations among pharmaceutical companies and public health organizations will facilitate innovation and distribution.
9. The impact of COVID-19 will lead to sustained interest in adult vaccination as part of comprehensive healthcare strategies.
10. Regulatory changes may streamline vaccine approval processes, accelerating the introduction of new products to the market.

Growing Prevalence of Infectious Diseases

The increasing incidence of infectious diseases such as influenza, pneumococcal infections, and hepatitis among adults, especially those with weakened immune systems or chronic conditions, is driving demand for adult vaccines to reduce morbidity and mortality.

Aging Population and Healthcare Expenditure

The global rise in the elderly population, who are more susceptible to vaccine-preventable diseases, along with increased healthcare spending, is enabling greater investment in adult immunization programs and vaccine accessibility.

Technological Advancements in Vaccine Development

Innovations in biotechnology, such as mRNA, recombinant, and conjugate vaccine platforms, have led to the creation of safer, more effective, and longer-lasting vaccines, accelerating adoption and expanding the range of diseases that can be targeted.

Government Initiatives and Public Awareness Campaigns

Government policies, funding, and public health campaigns are actively promoting adult vaccination, increasing awareness and acceptance, and supporting higher immunization rates through routine and targeted programs.

Rising Burden of Chronic Diseases

The growing prevalence of chronic conditions like diabetes and cardiovascular diseases, which increase vulnerability to infections, is boosting the need for preventive adult vaccines to reduce complications and healthcare costs.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.